News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoGen, Inc. (IMGN) Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma


9/23/2011 10:39:58 AM

WALTHAM, Mass., Sept. 22, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced its submission of the Investigational New Drug (IND) application for its IMGN529 product candidate to the U.S. Food and Drug Administration (FDA).

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES